NCT Number |
Title |
Conditions |
Interventions |
Sponsor/Collaborators |
Phases |
NCT03476876 |
Comparative Effectiveness of Two Acellular Matrices (Dermacell vs.
Integra) for Management of Deep Diabetic Foot Ulcers |
Diabetic Foot Ulcer|Deep Diabetic Foot Ulcer |
Device: Dermacell|Device: Integra |
Baylor College of Medicine|LifeNet Heath |
Phase 2|Phase 3 |
NCT03473301 |
A Study of UCB and MSCs in Children With CP: ACCeNT-CP |
Cerebral Palsy |
Biological: Infusion of allogeneic umbilical cord blood|Biological:
Infusion of MSCs |
Joanne Kurtzberg, MD|The Marcus Foundation|Duke University |
Phase 1|Phase 2 |
NCT03407170 |
Immunologic Determinants of Response to Pembrolizumab (MK-3475) in
Advanced Melanoma (MK-3475-161/KEYNOTE-161) |
Advanced Melanoma |
Biological: pembrolizumab |
Merck Sharp & Dohme Corp. |
Phase 2 |
NCT03396926 |
Pembrolizumab, Capecitabine, and Bevacizumab in Treating Patients With
Microsatellite Stable Colorectal Cancer That Is Locally Advanced, Metastatic,
or Cannot Be Removed by Surgery |
Microsatellite Stable|Mismatch Repair Protein Proficient|Stage III
Colorectal Cancer AJCC v7|Stage IIIB Colorectal Cancer AJCC v7|Stage IIIC
Colorectal Cancer AJCC v7|Stage IV Colorectal Cancer AJCC v7|Stage IVA
Colorectal Cancer AJCC v7|Stage IVB Colorectal Cancer AJCC v7 |
Biological: Bevacizumab|Drug: Capecitabine|Other: Laboratory Biomarker
Analysis|Biological: Pembrolizumab |
University of California, San Francisco|Merck Sharp & Dohme Corp. |
Phase 2 |
NCT03379493 |
Study of ET190L1-ARTEMIS??T Cells in Relapsed and Refractory CD19+
Non-Hodgkin's Lymphoma |
Lymphomas Non-Hodgkin's B-Cell |
Biological: ET190L1-ARTEMIS??T cells |
Eureka Therapeutics Inc.|Duke University|Duke Clinical Research Institute |
Phase 1 |
NCT03258008 |
Utomilumab and ISA101b Vaccination in Patients With HPV-16-Positive
Incurable Oropharyngeal Cancer |
Malignant Neoplasms of Ill-defined Secondary and Unspecified
Sites|Malignant Neoplasms of Lip Oral Cavity and Pharynx|Oropharyngeal Cancer |
Drug: Utomilumab|Biological: ISA101b |
M.D. Anderson Cancer Center|ISA Pharmaceuticals B.V.|Pfizer |
Phase 2 |
NCT03189134 |
Utilization of Confocal Microscopy During Cardiac Surgery |
Atrial Septal Defect |
Drug: Fluorescite|Device: Cellvizio 100 Series System with Confocal
Miniprobes |
Aditya Kaza|National Heart, Lung, and Blood Institute (NHLBI)|Boston
Children? |